This perspective suggests that Nrf2-based interventions could have therapeutic value not only at early but also at more advanced stages of ALS, when endogenous Nrf2 activity is already partially engaged [69]. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.